Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV® in Europe

[ad_1]

  • The settlement covers 29 international locations in Europe
  • Orexo will obtain double-digit royalties on future web gross sales
  • First launches are anticipated in H2, 2021

UPPSALA, Sweden, Dec. 7, 2020 /PRNewswire/ — Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) has entered into an unique licensing settlement with Accord Healthcare, for the commercialisation of ZUBSOLV® ((buprenorphine (as hydrochloride) and naloxone (as hydrochloride dihydrate)) sublingual pill. Licensed in Europe, ZUBSOLV® is indicated for adults and adolescents over 15 years of age for substitution therapy for opioid drug dependence, inside a framework of medical, social and psychological therapy, and who’ve agreed to be handled for dependancy.[1] ZUBSOLV® affords another therapy possibility for sufferers because it launches throughout 29 international locations in Europe. This settlement brings collectively the expertise of Orexo within the opioid dependancy market alongside the industrial attain of Accord Healthcare, who’re partnering along with a typical intention to make sure that folks have extra entry to therapy choices. There are estimated to be 1.3 million high-risk opioid customers in Europe,[2] but therapy charges are low with round 50 p.c of individuals with opioid dependence receiving some type of substitution therapy and this will fluctuate enormously between international locations.[3]

Beneath the phrases of the settlement, Orexo might be accountable for product provide and Accord will take duty for the commercialisation of ZUBSOLV®. Orexo will obtain double-digit royalties on future web gross sales.

Nikolaj Sørensen, President and CEO of Orexo AB, mentioned: “I’m enthusiastic about this new partnership with Accord and am trying ahead to creating ZUBSOLV® accessible to sufferers in Europe affected by opioid dependence. We’ve chosen Accord for his or her sturdy dedication to the dependancy subject and their profitable observe document in each generic and branded markets, which makes them ideally positioned to make ZUBSOLV® profitable within the aggressive European market.”

Paul Tredwell, VP Speciality Manufacturers, Accord Healthcare, Europe, Center East, and North Africa (EMENA) mentioned: “ZUBSOLV® is one among a number of medicines that we’re including to our rising speciality Central Nervous System franchise. This license settlement reaffirms our dedication to sufferers with dependancy by growing entry to a selection of medicines that may assist make an actual distinction to affected person lives.”

For additional data, please contact:

Orexo AB (publ.)




Nikolaj Sørensen, President and CEO

 

Lena Wange, IR & Communications Director

Tel: +46 (0)18 780 88 00

 

Tel: +46 (0)18 780 88 00

E-mail: ir@orexo.com

 

E-mail: ir@orexo.com

About Orexo

Develops improved prescription drugs and digital therapies addressing unmet wants throughout the rising area of substance use issues and psychological well being. The merchandise are commercialized by Orexo within the US or through companions worldwide. The primary market right now is the American marketplace for buprenorphine/naloxone merchandise, the place Orexo commercialize its lead product ZUBSOLV® for therapy of opioid use dysfunction. Complete web gross sales for 2019 amounted to SEK 844.8 million and the variety of staff was 127. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is out there as ADRs on OTCQX (ORXOY) within the US. The top workplace, the place analysis and improvement can be carried out, is located in Uppsala, Sweden.

For extra details about Orexo please go to,

www.orexo.com

. You may also comply with Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.

About Accord Healthcare

Headquartered within the United Kingdom (UK), Accord Healthcare Europe is among the quickest rising pharmaceutical firms in Europe. Accord has one of many largest market footprints of any European generic and biosimilars firms promoting generic medicines in over 80 international locations world wide. This international footprint allows us to ship very important, inexpensive medicines to nationwide well being methods supporting healthcare professionals to remodel affected person lives worldwide. Our method is agile and creative, all the time searching for to enhance our merchandise and sufferers’ entry to them. We’re pushed to assume otherwise and ship extra for the advantage of sufferers worldwide. www.accord-healthcare.com

Media Enquiries:

Accord Healthcare

Avril Fudge

PR & Comms Lead EMENA

PR@accord-healthcare.com

The data was submitted for publication at 8 am CET, on December 7, 2020.

[1] https://www.ema.europa.eu/en/documents/product-information/zubsolv-epar-product-information_en.pdf

[2] European Monitoring Centre for Medication and Drug Dependancy EMCDDA 2019 (https://www.emcdda.europa.eu ) 2019

[3] EMCDDA – Tackling Opioid Dependence (https://www.emcdda.europa.eu/best-practice/briefings/tackling-opioid-dependence_en ) 2019

This data was dropped at you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-enters-exclusive-license-and-supply-agreement-with-accord-healthcare-for-zubsolv—in-europe,c3249858

The next information can be found for obtain:

Cision View authentic content material:http://www.prnewswire.com/news-releases/orexo-enters-exclusive-license-and-supply-agreement-with-accord-healthcare-for-zubsolv-in-europe-301187064.html

SOURCE Orexo

Firm Codes: Stockholm:ORX, OTC-PINK:ORXOY, ISIN:SE0000736415, RICS:ORX.ST, Berlin:C5G, Frankfurt:C5G, OtherOTC:ORXOY

[ad_2]

Source link

Related posts

Leave a Comment